Trial · NCT00206323

A Randomized, Placebo-controlled, Tourette Syndrome Study.

NCT00206323, Phase 3, Completed, Baylor College of Medicine; results first posted 2017-11-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Randomized, Placebo-controlled, Tourette Syndrome Study. Trials, record NCT00206323. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00206323

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT number: NCT00206323
Status: Completed
Phases: Phase 3
Enrollment: 29 participants, actual
Lead sponsor: Baylor College of Medicine
Conditions: Tourette Syndrome
Interventions: Topiramate (drug), placebo/sugar pill
First posted: 2005-09-21
Last updated: 2020-02-12
Results first posted: 2017-11-06

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Total Tic Score at Day 70	baseline and Day 70	A component of the Yale Global Tic Severity Scale (YGTSS), the change from baseline in Total Tic Score (TTS) at visit 5 (day 70) is the pre-defined primary endpoint. The Total Tic Score (TTS) is a summation of the Total Motor Tic and Total Phonic Tic Scores. The Overall Impairment Rating is rated on a 50-point scale anchored by 0 (No impairment) and 50 (Severe impairment).

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Total Tic Score at Day 70	baseline and Day 70		units on a scale	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change From Baseline in Total Tic Score at Day 70	Placebo/Sugar Pill		-5.0	Standard Deviation 9.88	units on a scale
Change From Baseline in Total Tic Score at Day 70	Topiramate		-14.29	Standard Deviation 10.47	units on a scale

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo/Sugar Pill	14
Overall Study	STARTED	Topiramate	15
Overall Study	COMPLETED	Placebo/Sugar Pill	8
Overall Study	COMPLETED	Topiramate	12
Overall Study	NOT COMPLETED	Placebo/Sugar Pill	6
Overall Study	NOT COMPLETED	Topiramate	3

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	headache	General disorders	Placebo/Sugar Pill	3	14	3
other	headache	General disorders	Topiramate	3	15	3
other	diarrhea	Gastrointestinal disorders	Placebo/Sugar Pill	1	14	1
other	diarrhea	Gastrointestinal disorders	Topiramate	3	15	3
other	abdominal pain	Gastrointestinal disorders	Placebo/Sugar Pill	2	14	2
other	abdominal pain	Gastrointestinal disorders	Topiramate	2	15	2
other	drowsiness	General disorders	Placebo/Sugar Pill	2	14	2
other	drowsiness	General disorders	Topiramate	2	15	2
other	cognitive slowing	General disorders	Placebo/Sugar Pill	0	14	0
other	cognitive slowing	General disorders	Topiramate	1	15	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo/Sugar Pill
Total, all-cause mortality	Topiramate
Total, other adverse events	Placebo/Sugar Pill	8	14
Total, other adverse events	Topiramate	11	15
Total, serious adverse events	Placebo/Sugar Pill	0	14
Total, serious adverse events	Topiramate	0	15

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19726418	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Topiramate vs Placebo/Sugar Pill: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00206323

GET https://conductscience.org/api/trials/v1/NCT00206323/registered

API reference For AI assistants